coronavirus sars-cov

respiratory syndrome coronavirus

syndrome coronavirus

syndrome coronavirus sars-cov

ppd common

coronavirus sars-cov read

cov infection

sars cov

CPT: pharmacometrics & systems pharmacology

We modeled the viral dynamics of 13 untreated patients infected with severe acute respiratory syndrome‐coronavirus 2 to infer viral growth parameters and predict the effects of antiviral treatments. In order to reduce peak viral load by more than two logs, drug efficacy needs to be &gt; 90% if treatment is administered after symptom onset; an efficacy of 60% could be sufficient if treatment is initiated before symptom onset. Given their pharmacokinetic/pharmacodynamic properties, current investigated drugs may be in a range of 6–87% efficacy. They may help control virus if administered very early, but may not have a major effect in severely ill patients.

Timing of Antiviral Treatment Initiation is Critical to Reduce SARS‐CoV‐2 Viral Load